Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study

BACKGROUND: Metastatic and recurrent, platinum resistant cervix cancer has an extremely poor prognosis. The Gynecologic Oncology Group has studied >20 cytotoxic drugs or drug combinations in the second-line, phase II setting of advanced, drug resistant cervix cancer. METHODS: Nanoparticle, albumi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Alberts, David S., Blessing, John A., Landrum, Lisa M., Warshal, David P., Martin, Lainie P., Rose, Stephen L., Bonebrake, Albert J., Ramondetta, Lois M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459779/
https://ncbi.nlm.nih.gov/pubmed/22986144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.09.008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados